Article metrics

Download PDFPDF
1ISG-005 A cost-effectiveness analysis of nivolumab versus docetaxel for advanced nonsquamous non-small-cell lung cancer in second line in a healthcare setting

 

Online download statistics by month:

Online download statistics by month: March 2018 to January 2024

AbstractFullPdf
Mar 2018603
Apr 20185802
May 20182400
Jun 20181200
Jul 20183000
Aug 20182201
Sep 20184801
Oct 20182600
Nov 20183200
Dec 20182600
Jan 20191400
Feb 20192801
Mar 20194500
Apr 20195201
May 20195800
Jun 20192600
Jul 20193700
Aug 20191800
Sep 20192200
Oct 20193700
Nov 20193500
Dec 20191600
Jan 20201400
Feb 20201700
Mar 20201900
Apr 20201000
May 20202001
Jun 20201801
Jul 20201600
Aug 20201000
Sep 2020800
Oct 20202200
Nov 20203400
Dec 20201800
Jan 20214402
Feb 2021400
Mar 20215200
Apr 20211100
May 20211002
Oct 20211200
Nov 20212501
Dec 20212400
Jan 20221501
Feb 2022200
Mar 2022600
Apr 20221000
May 20221600
Jun 20221400
Jul 2022400
Aug 2022400
Sep 2022600
Oct 20221400
Nov 2022800
Dec 2022800
Jan 2023700
Feb 2023800
Mar 2023600
Apr 2023200
May 2023600
Jun 2023401
Jul 20231200
Aug 2023500
Sep 2023200
Nov 20232600
Dec 20231400
Jan 20241600
Total1275018